WIL Research Partners with Three S Japan
News May 24, 2013
WIL Research is partnering with Three S Japan, a company that provides support services in these industries, to represent its full portfolio of global safety assessment services in Japan.
WIL Research offers a blend of technical and regulatory expertise in discovery support, product safety toxicological research, metabolism, bioanalytical chemistry, analytical chemistry and formulation services.
They chose the Japan-based company to represent these services on the basis of its extensive network of clients, leadership experience with both pharmaceutical and chemical industry safety assessment, and its commitment to providing tailored, local client service.
“Three S Japan has a strong reputation serving the country’s pharmaceutical industry with high quality regulatory services underpinned by exceptional client focus,” said David Spaight, Chairman and CEO of WIL Research.
Spaight continued, “Through this partnership, clients will benefit from direct access to staff that can harness the full portfolio of WIL Research’s global services.”
CEO and President of Three S Japan, Koichi Hagita said, “WIL Research’s excellent reputation and our long-term client relationships and regulatory experience in the Japanese market will boost both our companies’ potential for growth.”
Three S Japan has operational centers in Tokyo and Osaka for pharmaceutical regulatory registration services.
The company provides toxicological support from pre-clinical to clinical development, and is experienced in the preparation, translation, and quality control checks of submission documents for New Drug Applications and Investigational New Drug applications.
Three S Japan also offers personalized consulting tailored to clients’ needs.
WIL Research was recently one of the winners of the CRO Leadership Award for Quality, awarded annually to leaders in quality, productivity, regulatory, accessibility, and reliability.
Uptake of Controlled Release Drug Delivery Technology Set to Increase?News
The increasing access to healthcare facilities and the bolstering need for drugs to be used orally has been driving the consumption of generic drugs among people across the world, which, in turn, is fueling the need for controlled release technology for drug delivery to suffice the availability of drugs in small dosages.READ MORE
Commonly Prescribed Painkillers: What Can be Done to Reduce Risk of Obesity and Sleep Deprivation?News
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.READ MORE
Safer Opioids: Separating Pain Relieving Properties from Dangerous Side EffectsNews
A group of researchers, led by Dr. Laura Bohn at The Scripps Research Institute, may have found a way to make opioids safer by separating the drugs' pain relieving effects from their most dangerous side effect, respiratory suppression, which, in very severe cases, causes patients to stop breathing and to die.READ MORE